Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Second Affiliated Hospital of Xi'an Jiaotong University
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a diagnosis of neovascular glaucoma (Stage 1-2-3)
Individuals who are ages 20-80 years old; male or female of chinese
Visual acuity of light perception or better in the study eye
Willing and able to comply with clinic visits and study-related procedures
Provide signed informed consent
You may not be if
Use of intraocular anti-VEGF agents in the study eye in the past 3 months.
Active ocular or periocular infection in the study eye
Uncontrolled Blood Pressure
Thromboembolism
Congestive Heart Failure
Renal Failure
History of myocardial infarction
History of Stroke
Pregnant or breast-feeding women
Participation in another simultaneous medical investigator or trial
Clareo Health | The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
